Japanese maker of blood glucose monitors and diagnostics, spun off from Panasonic's healthcare division.
Japanese maker of blood glucose monitors and diagnostics, spun off from Panasonic's healthcare division.
Gets much of its income from Ascensia, the diabetes-care business bought from Bayer in 2016, whose meters feed recurring test-strip sales, while laboratory instruments and hospital systems add a steadier second line. Originally Panasonic's healthcare arm, it passed to the private-equity investor KKR in 2014 and listed in 2021.
In one line: Japan's version of a smaller Abbott (diabetes care/diagnostics).
Moat: narrow (installed base, brand, regulatory licence). Installed meter base creates recurring test-strip sales; regulatory approvals are a barrier to entry.
Headquarters: Tokyo, Japan · Founded: 2014 · Employees: 8,647
Size PHC (6523.T) is a Japan Health Care company (Medical Specialties) with a market value of $1.02B, the 729th largest of 1,370 Japan companies the cockpit tracks. Shares closed at ¥1,286 on 18 Nov 2026.
Performance Over six months the shares gained 33.5%, against -7.9% for the median peer and -1.4% for the Japan market (cap-weighted) — 5th highest of 20 in its peer set.
Growth Revenue grew 2.7% over the last twelve months (peer median +11.0%); the operating margin is 8.0% (peer median 11.0%).
Valuation It trades at 7.5× forward earnings against a peer median of 18.7× (2nd cheapest of 14).
Price implies For today's price to make sense, revenue must grow about -4% a year for seven years (Req g). Recent delivered growth is +4%, so the hurdle is -8 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 0.3 points above its cost of capital (5.5% WACC).
Next results Next results expected around 5 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ¥371B | ¥364B | ¥362B | ¥354B | ¥356B |
| Revenue growth | — | +1% | +2% | -1% | — |
| Gross profit | ¥173B | ¥148B | ¥148B | ¥140B | ¥150B |
| EBITDA | ¥56.7B | ¥47.7B | ¥49.8B | ¥36.2B | ¥57.5B |
| Net income | ¥14.4B | ¥492M | ¥10.5B | -¥12.9B | -¥3.22B |
| Free cash flow | ¥42.3B | ¥33.4B | ¥30.3B | ¥26.7B | ¥9.86B |
| Capital expenditure | ¥9.30B | ¥9.09B | ¥11.6B | ¥14.6B | ¥11.5B |
| Total debt | ¥222B | ¥251B | ¥269B | ¥300B | ¥307B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 6523.T | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -5.4% | -1.9% | 9th lowest of 21 |
| 6-month return | +33.5% | -7.9% | 5th highest of 20 |
| Distance from 52-week high | -24.1% | -28.9% | 8th highest of 21 |
| Revenue growth (TTM) | +2.7% | +11.0% | 5th lowest of 20 |
| Operating margin | 8.0% | 11.0% | 7th lowest of 21 |
| Forward P/E | 7.5× | 18.7× | 2nd cheapest of 14 |
| Growth the price implies (Req g, 7 yrs) | -4.0% | 6.9% | 3rd least demanding of 14 |
| Growth delivered (Del g) | +3.5% | +11.7% | 2nd lowest of 14 |
| Hurdle (Req g minus delivered) | -7.6 pp | -3.0 pp | 4th least demanding of 14 |
| ROIC minus cost of capital | +0.3 pp | +3.1 pp | 9th lowest of 20 |
| EV / EBITDA | 6.1× | 9.1× | cheapest of 11 |
| Net debt / EBITDA | 3.2× | -0.2× | 3rd most indebted of 11 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| PHC 6523.T | Japan | $1.02B | +34% | +3% | 8% | 7.5× | -4.0% | +3.5% |
| Inno Laser Technology 301021.SZ | China | $1.03B | -33% | +17% | 9% | n/a | 50.8% | +8.6% |
| Beijing Wandong Medical Technology 600055.SS | China | $1.03B | -26% | -11% | -33% | n/a | n/a | n/a |
| Amoy Diagnostics 300685.SZ | China | $1.01B | -15% | +7% | 34% | 19.3× | 4.9% | +10.4% |
| Eckert & Ziegler EUZ.DE | Germany | $1.03B | -2% | +4% | 26% | 18.5× | 7.7% | +12.1% |
| Castle Biosciences CSTL | United States | $1.03B | +67% | +10% | -7% | n/a | 57.7% | +40.6% |
| Edan Instruments 300206.SZ | China | $1.00B | -19% | +14% | 17% | 18.0× | 6.9% | -2.9% |
| Ceribell CBLL | United States | $995M | +42% | +31% | -70% | n/a | n/a | n/a |
| IRadimed IRMD | United States | $1.05B | -9% | +11% | 32% | 34.3× | 18.5% | +21.5% |
| INKON Life Technology 300143.SZ | China | $985M | -23% | +22% | 12% | 50.3× | 10.7% | +12.9% |
| SI-BONE SIBN | United States | $1.06B | +59% | +14% | -8% | n/a | n/a | n/a |
| Guangzhou Hexin Instrument 688622.SS | China | $1.06B | +21% | -29% | -74% | n/a | n/a | n/a |
| Mingyue Optical Lens 301101.SZ | China | $1.07B | -4% | +14% | 25% | 31.6× | 8.8% | +8.8% |
| Mani 7730.T | Japan | $965M | -7% | +10% | 30% | 19.9× | 3.3% | +13.9% |
| Integra LifeSciences IART | United States | $1.08B | -10% | +1% | 12% | 6.0× | 5.9% | +3.6% |
| CLASSYS 214150.KS | South Korea | $1.08B | -60% | +16% | 43% | 13.7× | -9.2% | +34.5% |
| JINS 3046.T | Japan | $963M | -8% | +14% | 10% | 18.7× | -6.1% | +11.7% |
| Freenome FRNM | United States | $1.08B | n/a | n/a | 36% | n/a | n/a | n/a |
| Safilo SFL.MI | Italy | $953M | +42% | -4% | 9% | 15.8× | 1.3% | +4.7% |
| Alphatec ATEC | United States | $1.10B | -14% | +15% | -3% | 15.1× | n/a | n/a |
| Menicon 7780.T | Japan | $944M | +26% | +6% | 9% | 20.9× | n/a | n/a |